NEW BRUNSWICK, N.J., Dec. 13, 2016 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) today confirmed it has ended discussions with Actelion Pharmaceuticals Ltd. (SIX: ATLN) regarding a potential transaction. Johnson & Johnson was not able to reach an agreement that it believed would create adequate value for its shareholders.
About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,900 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.